Oculis Receives Positive FDA Feedback for MS Drug Development

Biopharmaceutical company Oculis has announced positive feedback from the U.S. Food and Drug Administration (FDA) regarding its plans to develop Privosegtor, a drug substance intended for the treatment of acute multiple sclerosis exacerbations.